Isoprenalina Phagecon (Isoprenaline Hydrochloride)

Isoprenaline binds to both β1 and β2 adrenergic receptors, activating adenylate cyclase and raising intracellular cyclic AMP levels. In the heart, this enhances calcium influx, speeding up the pacemaker activity and strengthening contractions. In the lungs, β2 stimulation relaxes bronchial smooth muscle, producing bronchodilation.

The dosage of Isoprenalina Phagecon is determined by the prescribing clinician based on the patient’s condition, weight, and response. It is typically administered as an intravenous infusion, with the rate adjusted to achieve the desired heart rate or bronchodilatory effect.

Safety data for isoprenaline in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Isoprenaline is a non‑selective β1/β2 agonist, offering both cardiac stimulation and bronchodilation, whereas agents like albuterol are selective for β2 receptors and primarily used for asthma. Compared with selective agents, isoprenaline has a broader cardiovascular effect, which can be advantageous in bradyarrhythmias but requires careful monitoring for cardiac side effects.

Isoprenalina Phagecon should be stored at ambient temperature, protected from light and moisture, and kept in its original sealed container. Do not freeze the solution. Before use, inspect for particulate matter or discoloration and discard if any abnormalities are observed.

The product is supplied as a sterile injectable solution for intravenous infusion. Administration is performed by qualified healthcare personnel, typically using a calibrated infusion pump to control the delivery rate, with continuous monitoring of cardiac parameters throughout the infusion.

Serious risks include life‑threatening arrhythmias, myocardial ischemia, severe hypotension, bronchospasm, and anaphylactic reactions. Immediate medical intervention is required if any of these events occur, and patients should be monitored closely during and after infusion.

Isoprenalina Phagecon is contraindicated in patients with uncontrolled tachyarrhythmias, severe coronary artery disease, or known hypersensitivity to isoprenaline. Caution is also advised for individuals with hypertension, hyperthyroidism, or those taking beta‑blockers, as the drug may produce adverse cardiovascular effects.